Dec 22, 2022 | Teresa Miceli
There is so much information being produced and shared at the American Society of Hematology (ASH) Annual Meeting, it is challenging to digest it all and distill it down. In review of the many screen shots I took of the presentation slides, one piece of information...
Dec 21, 2022 | Jessie Daw
Hope is important because it can make the present moment less difficult to bear. If we believe that tomorrow will be better, we can bear a hardship today. –Thich Nhat Hanh Reflecting on the opportunity I had to attend the 64th American Society of Hematology...
Dec 21, 2022 | Jessie Daw
Dr. Sigrun Thorsteinsdottir, MD, PhD, gave a comprehensive review of smoldering myeloma directed toward practitioners. The session was very informative and so I’d like to dedicate this blog to sharing this information from a patient’s perspective, as I’ll highlight...
Dec 19, 2022 | Teresa Miceli
Hello Myeloma Community. It is time for an update from the 64th American Society of Hematology (ASH) Annual Meeting. Arriving on Thursday, I had the opportunity to spend time with my dear friend, Angela Dispenzieri as we walked around the French Quarter and took in...
Dec 19, 2022 | Linda Huguelet
In some ways, a decade seems like a lifetime, but in other ways time flies by. 2013 was my first American Society of Hematology (ASH) Annual Meeting. That annual meeting, like the one this year, was held in New Orleans. The location may have been the same, but the...
Dec 19, 2022 | Michael Tuohy
Targets in myeloma are interesting and hopeful for our futures as bispecific antibodies continue to become a key treatment option. Using the immune system to fight multiple myeloma makes great sense to me. It’s exciting to follow trials targeting BCMA as part of the...